Biopharmaceutical News and Research

RSS

African Bundibugyo ebolavirus vaccine candidate to be advanced to clinical trials

Leading African biopharmaceutical company Minapharm Group, headquartered in Egypt with subsidiaries in Berlin, will receive up to US$16.5 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of a Bundibugyo ebolavirus vaccine candidate, strengthening efforts to develop vaccines to combat the fastest-growing and second-largest Ebola outbreak on record affecting the Democratic Republic of the Congo (DRC).

28 Aug 2026

New vaccination approach turns mosquito bites into immunity boosters

Researchers from WEHI (Melbourne, Australia) have discovered a new way to help prevent malaria that could one day transform mosquito bites from a source of deadly infection into immunity boosters against the disease.

13 Aug 2026

Air pollution may worsen rheumatoid arthritis symptoms and flare risk

A novel study shows that exposure to air pollution, especially fine particulate matter like dust, soot, and smoke (PM2.5), is associated with increased disease activity and flare risk in rheumatoid arthritis (RA).

5 Aug 2026

Digital twin of the gut-brain axis aims to advance neurostimulation therapies

The gut and brain are in constant conversation, exchanging signals that regulate hunger and digestion, as well as the body's response to stress.

3 Aug 2026

Insilico and Bora Pharmaceuticals forge strategic AI-driven drug discovery alliance

Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced a multi-target strategic alliance with Bora Pharmaceuticals Co., Ltd., a global leader in pharmaceutical manufacturing.

14 Jul 2026

Insilico Medicine founder to highlight sustainable longevity at BIO Asia-Taiwan

Dr. Alex Zhavoronkov, Founder and CEO of Insilico Medicine, has been invited to attend BIO Asia-Taiwan, which will be held from July 15 to 19 in Taiwan, China.

11 Jul 2026

ReproNovo announces first participant dosed in EU Phase 2 trial of RPN-002 for embryo implantation

ReproNovo, a clinical-stage biopharmaceutical company committed to addressing critical gaps in male and female fertility as well as women’s health, today announced that the first participant has been dosed in the Company’s EU Phase 2 clinical trial of RPN-002, entitled Nolasiban Optimized Regimen Dosing for Inhibition of Uterine Contractility (NORDIC).

6 Jul 2026

Insilico Medicine partners with Takeda for AI-driven drug discovery

Insilico Medicine, a leader in clinical-stage generative AI for drug discovery, today announced a strategic collaboration agreement with Takeda to use its proprietary end-to-end platform, Pharma.AI, to advance drug candidates across the company's therapeutic areas.

2 Jul 2026

How electrical engineering ensures accurate calibration and patient safety

Discover how electrical engineering supports calibration accuracy, device reliability, and patient safety in critical healthcare applications.

From Mesa Labs, Inc. 22 Jun 2026

Tirzepatide outperforms semaglutide for real-world weight loss

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have become massively popular for weight loss, but results vary from person to person and drug to drug.

16 Jun 2026

Single-dose gene therapy extends healthy lifespan in older mice

A research team from the Universitat Autònoma de Barcelona (UAB) has shown that a one-time administration of a gene therapy expressing the metabolic factor FGF21 can prolong health span in old mice.

15 Jun 2026

Philanthropic investment expands collaborative network for autoimmune research

NYU Langone Health today announced a new philanthropic investment from longtime supporters Judy and Stewart Colton as part of a $15 million gift shared across three Colton Consortium institutions: NYU Langone, Yale University, and Tel Aviv University.

10 Jun 2026

Bio-Rad receives MicroVal validation for EZ-Check™ Listeria testing kits

Bio-Rad Laboratories, Inc., a leader in life science research and clinical diagnostics products, today announced that MicroVal, the international certification organization for the validation and approval of alternative methods for the microbiological analysis of food and beverages, has approved EZ-Check Listeria spp. and EZ-Check Listeria monocytogenes Kits for the detection of Listeria spp. and Listeria monocytogenes in food products and environmental samples.

From Bio-Rad Laboratories 5 Jun 2026

ELRIG unveils keynote speakers for Drug Discovery 2026

ELRIG, a not-for-profit, volunteer-led organization dedicated to the global drug discovery community, today announced the keynote speaker program for Drug Discovery 2026.

From ELRIG (UK) Ltd. 3 Jun 2026

Building quality into drug development for safer, faster medicines

Discover how quality-driven drug development and AI accelerate safer medicines, reduce risk, and improve patient outcomes.

From Thermo Fisher Scientific – Pharmaceutical and Biopharmaceutical Solutions 2 Jun 2026

New trial aims to improve ATTR-CM diagnosis in heart failure

Transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly recognized yet frequently underdiagnosed cause of heart failure, particularly among older adults.

13 May 2026

Study improves prediction of dangerous outcomed from hypertrophic cardiomyopathy

A sweeping international study has identified ways to detect patients who are at serious risk of sudden death, heart failure or other dangerous outcomes from heart thickening known as hypertrophic cardiomyopathy.

13 May 2026

Enterprise Therapeutics achieves primary efficacy outcome in Phase 2 clinical trial for cystic fibrosis with novel inhaled ENaC blocker ETD001

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of people with respiratory diseases, today announced that its Phase 2 trial for ETD001, the Company's lead candidate for treatment of cystic fibrosis (CF), achieved its primary efficacy outcome.

From Enterprise Therapeutics Ltd 12 May 2026

What labs need to know about PFAS and ultrapure water quality

This interview with PFAS specialists reveals how ultrapure water impacts lab accuracy.

From Sartorius Lab Instruments GmbH & Co. KG 6 May 2026

New genetic tool tracks how bacteria spread between people

The research, published on April 24th, 2026, in Nature Microbiology, describes how the new tool, called TRAnsmision Clustering of Strains (TRACS), uses genomics to distinguish between closely related bacterial strains.

4 May 2026